8 papers in the library · 772 citations · publishing 2019-2025
Am J Bioeth January 13, 2025 Jamie Beachy, Willa Hall, Chantelle Thomas et al. 2 citations
As research therapists with hundreds of hours of clinical experience supporting adults with PTSD in Phase 3 trials of MDMA assisted-therapy (MAT), we appreciate the opportunity to respond to this s...
American Journal of Psychiatry 2025 Noam Goldway, Snehal Bhatt, Stephen Ross et al. 23 citations
PAT elicited durable shifts in personality, suggesting normalization of abnormal personality trait expression in AUD. Further study is needed to clarify whether PAT exerts its beneficial effects by reducing impulsiveness or whether impulsive individuals inherently respond better to PAT.
Am J Psychiatry 2025 Kelley C. O’donnell, Jim Grigsby, Charles S. Grob 9 citations
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
Int Rev Psychiatry September 11, 2024 Mary E. Yaden, Terence H. W. Ching, Noam Goldway et al. 2 citations
OBJECTIVE: The growth of psychedelic medicine creates new challenges in psychiatric education as physicians may soon be responsible for prescribing a number of psychedelic interventions. Despite this growing need for educated providers, very little is known about the training psychiatry residents receive in psychedelic medicine. We conducted a survey to determine the current educational...
Am J Psychiatry 2024 Kelley C. O’donnell, Brian T Anderson, Frederick S. Barrett et al. 31 citations
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
Am J Psychiatry 2024 Michael Alpert, Kelley C. O’donnell, Casey Paleos et al. 22 citations
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
JAMA Psychiatry August 24, 2022 Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. 668 citations
Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and...
Journal of Psychedelic Studies September 1, 2019 Kelley C. O’donnell, Sarah E. Mennenga, Michael P. Bogenschutz 15 citations
Background and aims Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments for major depressive disorder (MDD). Recent findings have suggested that psychedelic drugs may have a role in the treatment of depressive symptoms, and a number of groups are in the process of developing protocols to study this question...